Skip To Main Content
Priya Jain on Muck Rack

Priya Jain

  • SVP, Business Development and Strategy, Atkins
New Jersey
As seen in: Medium, HuffPost, Nature, The Times of India, Wiley Online Library, Slate, Royal Society of Chemistry, Thought Catalog, DEV Community, WARC and
Sales & Strategy Director at Atkins|Client champion connecting sales to strategy to business results|Infrastructure,Women Leadership,STEM advocate|Views my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Priya

Contact Priya, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Decision Tree Machine Learning Technique for Development of Efficient Fake News Detection

|
By Priya Jain
| ijfmr.com
Fake news dissemination through digital and social media platforms has become a significant challenge, influencing public opinion, spreading misinformation, and creating societal concerns. The development of an efficient fake news detection system is therefore essential to ensure the reliability and authenticity of online information.
Open in Who Shared Issue with article?

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

|
By Princess U. Ogbogu, Florence Roufosse, Praveen Akuthota, Piotr Kuna, Matthieu Groh, Andreas Reiter, Akira Yokota, Salman Siddiqui, Pim Mutsaers, Paneez Khoury, Lila Bahadori, Artur Bednarczyk, Gerben Bouma, Laura Brooks, Jorge A. Ferreira, Hanna Grindebacke, Calvin N. Ho, Priya Jain, Rebecca Palmer, Maria Jison, Amy D. Klion
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04315-8, published online 31 March 2026.
Open in Who Shared Issue with article?

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

|
By Princess U. Ogbogu, Florence Roufosse, Praveen Akuthota, Piotr Kuna, Matthieu Groh, Andreas Reiter, Salman Siddiqui, Pim Mutsaers, Paneez Khoury, Lila Bahadori, Artur Bednarczyk, Gerben Bouma, Laura Brooks, Jorge A. Ferreira, Priya Jain, Rebecca Palmer, Maria Jison, Amy D. Klion, Akira Yokota, Hanna Grindebacke, Calvin N. Ho
| Nature Verified
Abstract Benralizumab, an eosinophil-depleting anti-IL-5 receptor α antibody, has demonstrated efficacy in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis and shown promising results in hypereosinophilic syndrome (HES). NATRON was a randomized, double-blind placebo-controlled phase 3 study evaluating the efficacy and safety of benralizumab in FIP1L1::PDGFRA-negative HES. The primary endpoint was time to first HES flare.
Open in Who Shared Issue with article?
See all 166 licensed articles (171 Total)